Evidence map›Paper›PMID 31655204›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2020

The humanin peptide mediates ELP nanoassembly and protects human retinal pigment epithelial cells from oxidative stress.

Zhe Li, Parameswaran G Sreekumar, Santosh Peddi, David R Hinton, Ram Kannan, John Andrew MacKay

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Protein and polypeptide mediated delivery to the eye.Advanced drug delivery reviews · 2022
    Review
  6. Peptide-based coacervates in therapeutic applications.Frontiers in bioengineering and biotechnology · 2022
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Zhe LiDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy of the University of Southern California, Los Angeles, CA 90089, USA.
Parameswaran G SreekumarDoheny Eye Institute, Los Angeles, CA 90033, USA.
Santosh PeddiDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy of the University of Southern California, Los Angeles, CA 90089, USA.
David R HintonDepartment Ophthalmology, USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA; Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
Ram KannanDoheny Eye Institute, Los Angeles, CA 90033, USA.
John Andrew MacKayDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy of the University of Southern California, Los Angeles, CA 90089, USA; Department Ophthalmology, USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA; Department of Biomedical Engineering, Viterbi School of Engineering of the University of Southern California, Los Angeles, CA 90033, USA. Electronic address: jamackay@usc.edu.
Doheny Eye Institute · USSouthern California Eye Institute · USUniversity of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI OOKHTENS, MURAD · 1995 to 2020
$21.8M
Ophthalmic Therapeutics Engineering CoreP30EY029220 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Mahnaz Shahidi · 2018 to 2026
$6.5M
EXPERIMENTAL APPROACH TO MACULOPATHYR01EY001545 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HINTON, DAVID R. · 1985 to 2016
$6.0M
Protein-polymer nanomedicine for Sjogren's SyndromeR01EY026635 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Sarah F Hamm-Alvarez, John Andrew MacKay · 2017 to 2026
$4.6M
Intracellular switching using genetically engineered protein microdomainsR01GM114839 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACKAY, JOHN ANDREW · 2015 to 2019
$1.9M
NCI NIH HHS P30 CA014089NEI NIH HHS P30 EY029220NEI NIH HHS R01 EY001545NEI NIH HHS R01 EY026635NIDDK NIH HHS P30 DK048522NIGMS NIH HHS R01 GM114839
6 · The paper itself

Abstract

Humanin (HN) is a hydrophobic 24-amino acid peptide derived from mitochondrial DNA that modulates cellular responses to oxidative stress and protects human retinal pigment epithelium (RPE) cells from apoptosis. To solubilize HN, this report describes two genetically-encoded fusions between HN and elastin-like polypeptides (ELP). ELPs provide steric stabilization and/or thermo-responsive phase separation. Fusions were designed to either remain soluble or phase separate at the physiological temperature of the retina. Interestingly, the soluble fusion assembles stable colloids with a hydrodynamic radius of 39.1 nm at 37°C. As intended, the thermo-responsive fusion forms large coacervates (>1,000 nm) at 37°C. Both fusions bind human RPE cells and protect against oxidative stress-induction of apoptosis (TUNEL, caspase-3 activation). Their activity is mediated through STAT3; furthermore, STAT3 inhibition eliminates their protection. These findings suggest that HN polypeptides may facilitate cellular delivery of biodegradable nanoparticles with potential protection against age-related diseases, including macular degeneration.

Indexed as

ElastinIntracellular Signaling Peptides and ProteinsPeptidesApoptosisCells, CulturedEpithelial CellsHumansMacular DegenerationNanoparticlesOxidative StressRetinal Pigment EpitheliumElastinhumaninIntracellular Signaling Peptides and ProteinsPeptidesDynamic light scatteringLower critical solution temperatureMitochondria-derived peptideNanoparticle tracking analysisProtein-polymer

Identifiers

PMID31655204
PMCPMC7263384
OpenAlexW2981451853

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.